Mohamed Abouelhassan

Dr. Abouelhassan obtained his doctoral degree in Biochemistry from the Faculty of Medicine, Vrije Universiteit, Amsterdam, The Netherlands. His PhD focused on preclinical studies aimed at developing novel drugs and gene therapeutic agents that prevent doxorubicin cardiotoxicity. Dr. Abouelhassan did his postdoctoral research at Samuel Lunenfeld Research Institute, Mount Sinai Hospital. His research focused on epigenetic mechanisms of tumor evasion of immune surveillance. He then pursued training in Clinical Chemistry at the University of Toronto where he obtained his Diploma in Clinical Chemistry. He is a Certified Clinical Chemist and a Fellow of the Canadian Academy of Clinical Biochemistry.

Dr. Abouelhassan joined Medical Scientific Team, LifeLabs in 2018. Before that he was the Division Head for Clinical Biochemistry at the Queen Elizabeth Hospital, Health PEI. He is currently an Assistant Professor in the Department of Pathology, Faculty of Medicine, Dalhousie University.

Dr. Abouelhassan has a major interest in studying the impact of diurnal variation of analytes on their clinical utility. In addition, he has a long lasting interest in understanding the role of epigenetics in health and disease. A full list of publications can be found on his Google Scholar page at: https://scholar.google.ca/citations?hl=en&user=cxlJmy0AAAAJ&view_op=list_works